Participating Faculty: Balancing Therapeutic Safety and Efficacy to Improve Clinical and Economic Outcomes in Schizophrenia [CME/CPE]

Faculty

Daniel C. Javitt, MD, PhD

Director

Schizophrenia Research

Nathan Kline Institute

Orangeburg, New York

Professor and Director

Division of Experimental Therapeutics

Columbia University

New York, New York

Junqing Liu, PhD, MSW

Research Scientist

National Committee for Quality Assurance

Washington, District of Columbia

Editorial Support

Mei T. Liu, PharmD, BCPP

Clinical Assistant Professor

Department of Pharmacy Practice and Administration

Ernest Mario School of Pharmacy

Rutgers, the State University of New Jersey

New Brunswick, New Jersey

Psychiatry Clinical Pharmacist

Princeton House Behavioral Health

Princeton, New Jersey

Megan Maroney, PharmD, BCPP

Clinical Assistant Professor

Department of Pharmacy Practice and Administration

Ernest Mario School of Pharmacy

Rutgers, the State University of New Jersey

New Brunswick, New Jersey

Clinical Psychiatric Pharmacist

Monmouth Medical Center

Long Branch, New Jersey

A. Scott Mathis, PharmD

Regional Directory of Pharmacy

Pharmacy Department

Monmouth Medical Center

Long Branch, New Jersey

Faculty Disclosures

Daniel C. Javitt, MD, PhD, has disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:

Grant/research support: Pfizer Inc, Roche

Consultant: Bristol-Myers Squibb, EnVivo, Lilly, Omeros, Otsuka, SK Biopharmaceuticals, Sunovion, Takeda

Stock/shareholder: Glytech

Junqing Liu, PhD, MSW; Mei T. Liu, PharmD, BCPP; Megan Maroney, PharmD, BCPP; and A. Scott Mathis, PharmD, have no relevant financial relationships with commercial interests to disclose.

The American Journal of Managed Care

Publishing staff—Jeff D. Prescott, PharmD, RPh; Ida Delmendo; and Tara Petersen have no relevant financial relationships with commercial interests to disclose.

National Committee for Quality Assurance (NCQA)

Planning staff—Bart Ecker, Jackie Lombos, and Jennifer D’Alessandro have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Office of Continuing Professional Education

Planning staff—David Heckard; Steve Lin, PharmD, RPh; Donna Fausak; and Nathalie Harden have no relevant financial relationships with commercial interests to disclose.

Off-label Disclosure and Disclaimer

The contents of this CME/CE supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians and pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

For additional information about approved uses, including approved indications, contraindications, and warnings, participants are advised to consult prescribing information for all products discussed. The information provided in this CME/CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care, Pharmacy Times Office of Continuing Professional Education, and National Committee for Quality Assurance, or any of the companies that provided commercial support for this CME/CE activity.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Schizophrenia is a complex psychiatric disorder that is linked to substantial clinical and economic burdens. This supplement to The American Journal of Managed Care is designed to provide a detailed clinical understanding of schizophrenia, discuss the far-reaching impact of disease on patient health and quality of life, review the various pharmacologic and nonpharmacologic treatment options, and examine the managed care implications associated with schizophrenia and its management.

Download PDF: Participating Faculty: Balancing Therapeutic Safety and Efficacy to Improve Clinical and Economic Outcomes in Schizophrenia [CME/CPE]